JP2022512124A5 - - Google Patents

Info

Publication number
JP2022512124A5
JP2022512124A5 JP2021531891A JP2021531891A JP2022512124A5 JP 2022512124 A5 JP2022512124 A5 JP 2022512124A5 JP 2021531891 A JP2021531891 A JP 2021531891A JP 2021531891 A JP2021531891 A JP 2021531891A JP 2022512124 A5 JP2022512124 A5 JP 2022512124A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
group
activatable antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064779 external-priority patent/WO2020118109A2/en
Publication of JP2022512124A publication Critical patent/JP2022512124A/ja
Publication of JP2022512124A5 publication Critical patent/JP2022512124A5/ja
Priority to JP2024230664A priority Critical patent/JP7781254B2/ja
Priority to JP2025140806A priority patent/JP7906116B2/ja
Pending legal-status Critical Current

Links

JP2021531891A 2018-12-06 2019-12-05 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 Pending JP2022512124A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024230664A JP7781254B2 (ja) 2018-12-06 2024-12-26 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
JP2025140806A JP7906116B2 (ja) 2018-12-06 2025-08-26 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862776409P 2018-12-06 2018-12-06
US62/776,409 2018-12-06
US201862778062P 2018-12-11 2018-12-11
US62/778,062 2018-12-11
PCT/US2019/064779 WO2020118109A2 (en) 2018-12-06 2019-12-05 Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024230664A Division JP7781254B2 (ja) 2018-12-06 2024-12-26 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2022512124A JP2022512124A (ja) 2022-02-02
JP2022512124A5 true JP2022512124A5 (cg-RX-API-DMAC7.html) 2022-12-28

Family

ID=69024693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531891A Pending JP2022512124A (ja) 2018-12-06 2019-12-05 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
JP2024230664A Active JP7781254B2 (ja) 2018-12-06 2024-12-26 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024230664A Active JP7781254B2 (ja) 2018-12-06 2024-12-26 マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法

Country Status (15)

Country Link
US (4) US12049505B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890764A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022512124A (cg-RX-API-DMAC7.html)
KR (3) KR102958919B1 (cg-RX-API-DMAC7.html)
CN (2) CN113271956B (cg-RX-API-DMAC7.html)
AU (3) AU2019394972B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010433A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120327A1 (cg-RX-API-DMAC7.html)
IL (1) IL283756A (cg-RX-API-DMAC7.html)
MX (1) MX2021006429A (cg-RX-API-DMAC7.html)
MY (1) MY205459A (cg-RX-API-DMAC7.html)
SG (1) SG11202105476XA (cg-RX-API-DMAC7.html)
TW (2) TWI855012B (cg-RX-API-DMAC7.html)
WO (1) WO2020118109A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202405610B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
US20220251206A1 (en) * 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CN110702669A (zh) * 2019-09-19 2020-01-17 湖北科益药业股份有限公司 一种快速阿昔洛韦凝胶含量测定的方法
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
AU2021326469C1 (en) * 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
MX2024004301A (es) 2021-10-08 2024-04-26 Cytomx Therapeutics Inc Construcciones de citocinas activables y metodos combinados.
WO2023060156A2 (en) 2021-10-08 2023-04-13 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
KR102648687B1 (ko) 2022-01-25 2024-03-15 (주) 아이오에이 자동판매장치
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス,インク. 活性化可能な二重アンカー型マスク化分子及びその使用方法
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4260907A1 (en) * 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
JP2025525868A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス,インク. プロテアーゼ切断性部分及びその使用方法
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
TW202424184A (zh) 2022-08-01 2024-06-16 美商Cytomx生物製藥公司 蛋白酶可切割部分及其使用方法
US20260015425A1 (en) 2022-08-01 2026-01-15 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
EP4694934A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN122349537A (zh) 2023-12-01 2026-07-07 阿布林克斯有限公司 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP0904386A2 (en) 1996-05-10 1999-03-31 Danisco A/S alpha-GLUCURONIDASES OF ASPERGILLUS, PRODUCTION THEREOF AND THEIR USES
AUPO930697A0 (en) 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
AU4688499A (en) 1998-10-23 2000-05-15 Human Genome Sciences, Inc. Fibroblast growth factor receptor-5
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
AU7833000A (en) * 1999-09-27 2001-04-30 Human Genome Sciences, Inc. 38 human secreted proteins
CA2388019A1 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001055448A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
WO2002006481A1 (fr) * 2000-07-14 2002-01-24 Japan Science And Technology Corporation Cible d'un agent anticancereux
EP1328632A2 (en) 2000-08-04 2003-07-23 Eli Lilly And Company C1q-related factor, homologous polypeptides and therapeutic uses thereof
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
WO2002038796A2 (en) 2000-11-08 2002-05-16 Beth Israel Deaconess Medical Center, Inc. Methods for determining protease cleavage site motifs
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US7630836B2 (en) * 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
US20030134298A1 (en) 2001-07-03 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
US7439319B2 (en) 2001-09-14 2008-10-21 Burnham Institute For Medical Research Selective substrates for matrix metalloproteinases
WO2003038083A1 (en) 2001-10-29 2003-05-08 Bayer Healthcare Ag Regulation of human type i adenylate cyclase
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
US20060009840A1 (en) 2002-03-15 2006-01-12 Hossainy Syed F Carrier for releasing a therapeutic substance in response to the presence of an enzyme
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
JP2003339385A (ja) * 2002-05-29 2003-12-02 Toyobo Co Ltd 新規3−ヒドロキシ酪酸脱水素酵素遺伝子、新規3−ヒドロキシ酪酸脱水素酵素の製造法、ならびに、新規3−ヒドロキシ酪酸脱水素酵素を用いたケトン体の測定方法および測定用組成物
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20040216190A1 (en) * 2003-04-28 2004-10-28 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2004099254A2 (en) 2003-05-06 2004-11-18 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US9079936B2 (en) 2003-07-01 2015-07-14 University Of Maryland, Baltimore Derivatives of APF and methods of use
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
AU2006226192A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
WO2007027935A2 (en) 2005-08-31 2007-03-08 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
EP1993608A1 (en) 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
WO2010088691A2 (en) 2009-02-02 2010-08-05 Washington State University Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
MX2012002719A (es) 2009-09-02 2012-06-28 Univ Kansas State Ensayos opticos y de imagenes por resonancia magnetica (mri) para proteasas.
WO2011036297A2 (de) * 2009-09-27 2011-03-31 Ruhr-Universität-Bochum Verfahren zur therapie und diagnose von morbus alzheimer
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
BR112012029666A2 (pt) 2010-05-20 2020-10-06 Allergan, Inc. toxinas clostridiais degradáveis
GB201009271D0 (en) 2010-06-02 2010-07-21 Promar As Compositions
PL391627A1 (pl) 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
US20120107894A1 (en) * 2010-10-28 2012-05-03 Joule Unlimited Technologies, Inc. Methods and Compositions for the Recombinant Biosynthesis of Terminal Olefins
JP6096667B2 (ja) * 2010-11-17 2017-03-15 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se テルペンの生体触媒環化のための方法及びその方法で使用され得るシクラーゼ変異体
EP2709666B1 (en) 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
US20140193342A1 (en) 2011-06-10 2014-07-10 The Regents Of The University Of California Enzyme directed assembly of particle theranostics
RU2639526C2 (ru) 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
JP6605957B2 (ja) 2013-01-04 2019-11-13 シトムクス セラピューティクス,インコーポレイティド 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
US20140273089A1 (en) * 2013-03-14 2014-09-18 Amgen, Inc. Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
HK1215592A1 (zh) * 2013-04-16 2016-09-02 Commonwealth Scientific And Industrial Research Organisation G蛋白偶联受体库
EP2988786A4 (en) 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
SG11201509595PA (en) 2013-05-28 2015-12-30 Dcb Usa Llc Antibody locker for the inactivation of protein drug
BR112015030514A2 (pt) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
US12374421B2 (en) * 2013-06-10 2025-07-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2014202616A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
KR102208963B1 (ko) * 2014-05-14 2021-01-28 삼성전자주식회사 신규한 아크릴산 생성 경로를 갖는 미생물 및 이를 이용한 아크릴산 생산 방법
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
IL300408B2 (en) * 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
KR20160107038A (ko) * 2015-03-03 2016-09-13 경남대학교 산학협력단 마이오신 아형을 분석하는 방법
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
CN107709356A (zh) 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
US20170191094A1 (en) * 2015-12-31 2017-07-06 Synthetic Genomics, Inc. Expression of type i fatty acid synthase genes in eukaryotic algae
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
US10337051B2 (en) * 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
EP3526326A4 (en) 2016-10-12 2020-07-29 The Regents of The University of Colorado, A Body Corporate NEW MODIFIED AND CHEMERICAL NUCLEASES
EP3583217A4 (en) * 2017-02-17 2021-04-07 Hyasynth Biologicals Inc. PROCESS AND CELL LINE FOR THE PRODUCTION OF POLYKETIDES IN YEAST
CN107723311A (zh) * 2017-11-28 2018-02-23 中国科学院遗传与发育生物学研究所 一种与植物种子粒重相关的TaCKX2‑3D蛋白及其编码基因与应用
WO2019161251A1 (en) * 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof
EP3864407A4 (en) 2018-10-11 2022-07-13 Northwestern University BIOMARKERS OF CHRONIC KIDNEY DISEASE IN LIVER TRANSPLANT RECIPIENTS
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法

Similar Documents

Publication Publication Date Title
JP2022046569A5 (cg-RX-API-DMAC7.html)
US11986535B2 (en) Method of producing an immunoligand/payload conjugate
JP2021178823A5 (cg-RX-API-DMAC7.html)
JP2016521707A5 (cg-RX-API-DMAC7.html)
JP2018504925A5 (cg-RX-API-DMAC7.html)
JP2026004397A5 (cg-RX-API-DMAC7.html)
JP2022064924A5 (cg-RX-API-DMAC7.html)
JP2017509594A5 (cg-RX-API-DMAC7.html)
JP2023547978A5 (cg-RX-API-DMAC7.html)
HRP20220631T1 (hr) Supstrati koje mogu cijepati matrične metaloproteaze i serinske proteaze, te postupci njihove uporabe
Dimasi et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators
US20100189727A1 (en) Masking Ligands For Reversible Inhibition Of Multivalent Compounds
RU2016135239A (ru) Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
RU2015156888A (ru) Композиции и методы конъюгирования активируемых антител
JP2012514982A5 (cg-RX-API-DMAC7.html)
WO2021132166A1 (ja) エリブリンをベースとする抗体-薬物コンジュゲートの製造方法
JP2003522117A (ja) 治療薬の送達のための二機能性分子
CN121949565A (zh) 靶向表皮生长因子受体的组合物及其制备和使用方法
Sheikholvaezin et al. Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase
CN116096747A (zh) 免疫原性降低型低分子抗体及其制造法
NZ733811B2 (en) Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
NZ772089B2 (en) Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
US20190270828A1 (en) Tandem antibodies
NZ772087B2 (en) Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof